The board of directors of Bio-Techne Corporation (Nasdaq:TECH) declared on Thursday its dividend of USD0.32 per share of its common stock for the quarter ended 30 June 2017.

This quarterly dividend is due on 1 September 2017 to all common shareholders of record as of 18 August 2017.

According to the company, it develops high quality purified proteins––notably cytokines and growth factors, antibodies, immunoassays, as well as biologically active small molecule compounds and ACD's in situ hybridization detection products --- which are sold to biomedical researchers and clinical research laboratories.

With thousands of products in its portfolio, the company aids in drug discovery efforts, provides accurate clinical tests and diagnoses, generated approximately USD563m in net sales in fiscal 2017 and has approximately 1,800 employees worldwide.